Free Trial
NYSE:ZYME

Zymeworks (ZYME) Stock Price, News & Analysis

Zymeworks logo
$12.95 -0.13 (-0.99%)
As of 03:59 PM Eastern

About Zymeworks Stock (NYSE:ZYME)

Key Stats

Today's Range
$12.78
$13.25
50-Day Range
$11.22
$13.10
52-Week Range
$8.83
$17.70
Volume
240,997 shs
Average Volume
582,385 shs
Market Capitalization
$901.02 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$21.00
Consensus Rating
Moderate Buy

Company Overview

Zymeworks Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
42nd Percentile Overall Score

ZYME MarketRank™: 

Zymeworks scored higher than 42% of companies evaluated by MarketBeat, and ranked 640th out of 922 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Zymeworks has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 7 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Zymeworks has only been the subject of 3 research reports in the past 90 days.

  • Read more about Zymeworks' stock forecast and price target.
  • Earnings Growth

    Earnings for Zymeworks are expected to decrease in the coming year, from ($1.39) to ($1.64) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Zymeworks is -8.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Zymeworks is -8.61, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Zymeworks has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Zymeworks' valuation and earnings.
  • Percentage of Shares Shorted

    10.16% of the float of Zymeworks has been sold short.
  • Short Interest Ratio / Days to Cover

    Zymeworks has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Zymeworks has recently decreased by 4.31%, indicating that investor sentiment is improving.
  • Dividend Yield

    Zymeworks does not currently pay a dividend.

  • Dividend Growth

    Zymeworks does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    10.16% of the float of Zymeworks has been sold short.
  • Short Interest Ratio / Days to Cover

    Zymeworks has a short interest ratio ("days to cover") of 12.1, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Zymeworks has recently decreased by 4.31%, indicating that investor sentiment is improving.
  • News Sentiment

    Zymeworks has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for Zymeworks this week, compared to 6 articles on an average week.
  • MarketBeat Follows

    1 people have added Zymeworks to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Zymeworks insiders have bought more of their company's stock than they have sold. Specifically, they have bought $1,460,849.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 1.92% of the stock of Zymeworks is held by insiders.

  • Percentage Held by Institutions

    92.89% of the stock of Zymeworks is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Zymeworks' insider trading history.
Receive ZYME Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zymeworks and its competitors with MarketBeat's FREE daily newsletter.

ZYME Stock News Headlines

Zymeworks (NYSE:ZYME) Receives "Neutral" Rating from HC Wainwright
Thirty-Year “Wonder Material” Finally Ready for Factory Floors
A Nobel-recognized material once trapped in research labs is finally ready for the real world. After a 90% cost breakthrough, this wonder-material is being tested by aerospace giants, battery developers, and chip makers alike. Now, a new briefing reveals the companies best positioned to profit from its mass adoption.
See More Headlines

ZYME Stock Analysis - Frequently Asked Questions

Zymeworks' stock was trading at $14.64 at the start of the year. Since then, ZYME shares have decreased by 11.8% and is now trading at $12.91.

Zymeworks Inc. (NYSE:ZYME) released its quarterly earnings data on Thursday, May, 8th. The company reported ($0.30) earnings per share for the quarter, beating the consensus estimate of ($0.45) by $0.15. The firm's quarterly revenue was up 170.3% on a year-over-year basis.

Zymeworks (ZYME) raised $65 million in an initial public offering on Friday, April 28th 2017. The company issued 4,500,000 shares at a price of $13.00-$16.00 per share. Citigroup, Barclays, Wells Fargo Securities and Canaccord Genuity served as the underwriters for the IPO and Cormark Securities was co-manager.

Shares of ZYME stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Zymeworks investors own include Voyager Therapeutics (VYGR), Humana (HUM), American Water Works (AWK), Waste Connections (WCN), The RMR Group (RMR), AU Optronics (AUOTY) and DiamondRock Hospitality (DRH).

Company Calendar

Last Earnings
5/08/2025
Today
7/08/2025
Next Earnings (Estimated)
7/30/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:ZYME
Previous Symbol
NASDAQ:ZYME
Employees
460
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$21.00
High Stock Price Target
$30.00
Low Stock Price Target
$13.00
Potential Upside/Downside
+60.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.90
Research Coverage
10 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$118.67 million
Net Margins
-182.75%
Pretax Margin
-189.75%

Debt

Sales & Book Value

Annual Sales
$93.38 million
Price / Cash Flow
N/A
Book Value
$6.63 per share
Price / Book
1.97

Miscellaneous

Free Float
67,556,000
Market Cap
$910.07 million
Optionable
Optionable
Beta
1.19

Social Links

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NYSE:ZYME) was last updated on 7/8/2025 by MarketBeat.com Staff
From Our Partners